Observational studyCardiovascular and interventional radiology2026
Percutaneous Cryoablation of Clinical T1b Renal Tumors: A Tertiary Cancer Center Experience.
Observational study in Cardiovascular and interventional radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comment on: Percutaneous Cryoablation of Clinical T1b Renal Tumors: A Tertiary Cancer Center Experience.Cardiovascular and interventional radiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the oncologic and survival outcomes of patients who underwent cryoablation (CA) for T1b renal masses. MATERIALS AND
methodsThis retrospective observational cohort study was conducted in accordance with the STROBE guidelines. All patients with renal tumors from 4.1 cm to 7 cm in our renal ablation registry who underwent CA between January 2008, and June 2024 were included in our study. We excluded patients with renal tumors < 4 cm and patients who underwent microwave or Radiofrequency ablation, for T1b lesions. We compiled data on age, sex, tumor location and size, histopathology, procedure-related variables, and outcomes. The Kaplan-Meier methodology was used to estimate survival probabilities.
resultsFifty-one patients underwent 52 CA for 51 renal tumors. Overall, 39% of patients had a concomitant non-renal malignancy. The median tumor diameter was 4.5 cm. The median RENAL nephrometry score was 5. Most tumors (82%) were proven to be RCC by biopsy. Twenty-three patients underwent only cryoablation and 28 underwent a combination of embolization and cryoablation. Two patients (4%) experienced recurrence at the ablation site (30 months and 41.5 months after the ablation). Among the 27 patients with de novo histologically proven renal cell carcinoma included in the survival analysis, the median overall survival duration was 6.1 years, and the 5-year Local recurrence, disease and metastatic free survival rates were 87%, 83%, and 96%, respectively.
conclusionCA (with and without embolization) is safe and effective in patients with clinical T1b RCC who are not candidates for surgery. Cryoablation offers durable local oncologic control and favorable long-term survival outcomes in appropriately selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.